Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
MAINZ, Germany, July 21, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2026 on Tuesday, August 4, 2026....
-
MAINZ, Deutschland, 21. Juli 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Dienstag, den 4. August 2026, die Ergebnisse für das zweite Quartal 2026...
-
Pluristyx secures a Series A priced round initial close led by a multinational Fortune 500 company to accelerate growth and expand its stem cell platform.
-
Cancer treatment is undergoing one of the most significant transformations in modern medical history.
-
Pluristyx issued Japan patent allowance for next-gen synthetic mRNA, accelerating non-viral, footprint-free iPSC generation for regenerative medicine
-
Yet one of oncology's greatest challenges, Glioblastoma, remains largely unsolved.
-
Phase 2 and Phase 3 trials are reshaping expectations across obesity, oncology, gene editing, autoimmune disease, and neurological disorders.
-
Nanomedicine expert joins Massachusetts Biomedical Initiatives (MBI) lab in Worcester to advance RNA therapeutics for musculoskeletal disease
-
RNA Edge combines AI sequence optimization, novel genetic parts, and validation in application-relevant cell models to improve expression and half-life.
-
BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidatesBioNTech co-founders Ugur Sahin and Özlem Türeci will...